TGFB1

Overview

TGFB1 encodes transforming growth factor beta-1 (TGF-β1), a secreted cytokine and multifunctional signaling molecule in the transforming growth factor beta family. It is a central regulator of cell growth, differentiation, extracellular matrix production, immune modulation, wound repair, and tissue remodeling. Through canonical Smad2/3 signaling and related non-canonical pathways, TGF-β1 can promote either homeostatic repair or pathological fibrosis depending on cellular context, dose, and disease state.

In biomedical research, TGFB1 is frequently studied as both a mechanistic driver and a therapeutic target. It is especially relevant in fibrosis, cancer progression, immune suppression, cartilage regeneration, diabetic wound healing, and transplant biology. In tumors, TGFB1 is often associated with immunosuppressive microenvironments and poor prognosis; in regenerative settings, it can support matrix deposition and lineage-specific differentiation, including chondrogenesis and wound repair.

Recent Publications Summary

Recent studies have established TGF-β1 as a central mediator in multiple fibrotic diseases, including lung fibrosis, cardiac fibrosis, liver fibrosis, and diabetic nephropathy. Atg5 deficiency in lung mesenchymal cells promoted TGF-β1-induced oxidative stress and cellular senescence in fibroblasts, leading to increased myofibroblast differentiation and extracellular matrix deposition in bleomycin-induced fibrosis models 42392083Jul. In metabolic dysfunction-associated steatohepatitis, thrombospondin-1 (THBS1) was shown to activate latent TGF-β1, contributing to stromal-immune communication in fibroinflammatory remodeling 42266095Jun. Similarly, in cardiac fibrosis associated with diabetic cardiomyopathy, TGF-β1 acts through the Smad2/3 signaling pathway to promote fibrotic gene expression, a mechanism effectively modulated by oleuropein 42151222May. Network pharmacology studies identified TGFB1 as a core target in the therapeutic effects of fermented Astragalus membranaceus against diabetic nephropathy 42009593Apr.

TGF-β1 signaling mechanisms have been extensively characterized in fibrotic and inflammatory pathologies. CHI3L1 amplifies TGF-β1-induced fibroblast responses—including myofibroblast transformation, migration, and invasion—through enhancement of SMAD, AKT, and ERK signaling pathways 42048160Apr. In cerebral ischemia-reperfusion injury, a combination of active compounds from Salvia miltiorrhiza and safflower reduced brain injury via modulation of the TGF-β1/Smad3 pathway 42102961May. In allergic rhinitis, TGFB1 was identified as a downregulated immunoregulatory biomarker with significant correlations to M2 macrophage infiltration and activated memory CD4+ T cells 42543752Aug.

Multiple therapeutic strategies have successfully targeted TGF-β1 to attenuate fibrotic conditions. Compound 6 isolated from Penicillium soli suppressed TGF-β1-driven fibroblast activation and extracellular matrix production in vitro and alleviated bleomycin-induced pulmonary fibrosis in mice 42187025May. A bivalent anti-CTGF aptamer that disrupts the interaction between CTGF and TGF-β1 markedly decreased fibrotic markers and α-smooth muscle actin expression in liver fibrosis models 41955940Apr. A novel hydrophobic tag-based JNK1 degrader effectively inhibited TGF-β1-induced epithelial-mesenchymal transition through ubiquitin-proteasome and autophagy-lysosome pathways 41856067Mar. Combined targeting of CHI3L1 and PD-1 demonstrated superior antifibrotic efficacy compared to monotherapy 42048160Apr.

Beyond fibrosis, TGF-β1 plays important roles in differentiation and immunomodulation. In chondrogenic differentiation of human periosteum-derived cells, TGF-β1 consistently promoted cartilage matrix production, including collagen type II and aggrecan deposition 42102888May. In retinal pigment epithelial cells, RET inhibition by selpercatinib suppressed TGF-β1-induced epithelial-mesenchymal transition, a key process in fibrotic ocular diseases 41997282Apr. tumor-derived extracellular vesicles engineered to downregulate TGF-β1 while overexpressing IL-18 demonstrated enhanced immunogenic potential for dendritic cell-based antitumor vaccines 41780683Mar. Collectively, these studies underscore TGF-β1 as a multifaceted regulator with broad relevance to fibrosis, epithelial-mesenchymal transition, differentiation, and immune responses.

What Changes, What Holds

1. TGF-β1 is now implicated as a mechanistic amplifier across several fibrotic organs, not just a general fibrosis mediator
REINFORCES These studies sharpen the baseline view that TGFB1 is a central driver of fibrosis by tying it to specific upstream and downstream modifiers in lung, liver, heart, and kidney disease 42392083Jul42266095Jun42151222May42009593Apr. The main change is not a new role but a more detailed map of how latent activation, oxidative stress, senescence, and Smad2/3-linked transcription can converge on the same profibrotic output.

2. TGF-β1 signaling remains a core inflammatory-fibrotic axis, with new evidence adding immune-cell context and pathway crosstalk
REINFORCES The new work strengthens the established account of TGFB1 as a multifunctional regulator in fibrosis and immune modulation by showing that fibroblast activation can be intensified through SMAD, AKT, and ERK cooperation, and that disease-associated expression changes track with immune infiltration patterns 42048160Apr42543752Aug. Nothing here displaces the baseline; it makes the immunoregulatory and signaling-network aspects more explicit.

3. Directly interrupting TGF-β1-linked profibrotic signaling is increasingly actionable, but the therapeutic logic is still pathway-specific rather than entity-wide
REINFORCES These findings reinforce TGFB1 as a therapeutic target in fibrosis by showing that several distinct interventions can blunt TGF-β1-driven matrix production, myofibroblast activation, and EMT 42187025May41955940Apr41856067Mar. The important implication is not that TGF-β1 is newly targetable, but that multiple nodes around its signaling axis can be exploited, which supports the baseline’s therapeutic framing while leaving comparative durability and safety unsettled.

4. TGF-β1’s role extends beyond repair and fibrosis into cartilage formation, ocular EMT, and vaccine engineering, but these are additions rather than reversals
NEW DIRECTION The new studies broaden the baseline by placing TGFB1 in chondrogenic matrix deposition, retinal epithelial-mesenchymal transition, and immune-vaccine design, roles the Overview does not specifically cover 42102888May41997282Apr41780683Mar. These findings do not contradict its established functions in differentiation and immunomodulation; they extend them into more specific translational settings.

Overview update candidates: mechanistic detail on fibrotic amplification; immune-context associations and pathway crosstalk; cartilage matrix production; ocular EMT; and engineered immunogenicity.